Reviva Pharmaceuticals Holdings, Inc. (OTCPK: RVPH)
Health Care · Pharmaceuticals · US
$0.48
-1.43% today · -95.5% 1Y
Reviva Pharmaceuticals Holdings, Inc. (OTCPK: RVPH) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.33M and employs 14 people.
Over the last twelve months the share price has lost 95.5%, trading between 0.26 and 17.20.
Tweenvest scores Reviva Pharmaceuticals Holdings, Inc. across four factors: quality 26/100. Its strongest factor is quality.
RVPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.33M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.75
- Dividend yield
- —
- Beta (5Y)
- 0.49
- 52-week high
- $17.20
- 52-week low
- $0.26
- Avg volume (3M)
- —
- Shares outstanding
- 13.11M
- Employees
- 14
- Next earnings
- —
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
- Founded
- 2018
- Listed since
- Dec 15, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.35 | +0.16% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.